Home › Funds › Siren, L.L.C. › ARWR

Siren, L.L.C. position in ARWR

Arrowhead Pharmaceuticals, Inc. · Health Care

Siren, L.L.C. reported holding 2,290,476 shares of ARWR (Arrowhead Pharmaceuticals, Inc.) in its Q3 2026 13F filing — a position valued at US$149.9M, representing 3.56% of its reported portfolio and ranking #8 among its reported holdings. Siren, L.L.C. has disclosed ARWR holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)2.29M sh
Reported value held$149.91M
Portfolio Weight3.56%
First reportedQ3 2024
Last changeAdd
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Siren, L.L.C.'s ARWR position evolved

Siren, L.L.C. first disclosed a stake in ARWR in Q3 2024 at 2,458,778 shares (US$47.6M). The position peaked in Q3 2026 at 2,290,476 shares, worth US$149.9M. Across 9 filings, Siren, L.L.C. increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,290,476 shares valued at US$149.9M — an increase of 575,000 shares quarter over quarter.. Notable position changes include a 44% trim in Q4 2025 (shares fell 6% over the following quarter), a 34% increase in Q3 2026 (shares fell 25% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 2.46M $47.63M New
Q4 2024 2.90M $54.55M Add
Q1 2025 2.67M $34.01M Reduce
Q2 2025 2.67M $42.18M Hold
Q3 2025 2.67M $92.08M Hold
Q4 2025 1.50M $99.62M Reduce
Q1 2026 1.62M $101.29M Add
Q2 2026 1.72M $139.83M Add
Q3 2026 2.29M $149.91M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (Arrowhead Pharmaceuticals, Inc.) is a Health Care company. 50 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has Siren, L.L.C. held ARWR?

Siren, L.L.C. has disclosed ARWR holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Siren, L.L.C.'s current position in ARWR?

As of Q3 2026, Siren, L.L.C. holds 2.29M shares of ARWR (Arrowhead Pharmaceuticals, Inc.), valued at $149.91M, representing 3.56% of its reported portfolio and ranking #8.

Has Siren, L.L.C. been buying or selling ARWR?

In the latest 13F filing (Q3 2026), Siren, L.L.C. increased its position in ARWR. The position peaked in Q3 2026 at 2.29M shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.